` CNTB (Connect Biopharma Holdings Ltd) vs S&P 500 Comparison - Alpha Spread

CNTB
vs
S&P 500

Over the past 12 months, CNTB has significantly outperformed S&P 500, delivering a return of +125% compared to the S&P 500's +15% growth.

Stocks Performance
CNTB vs S&P 500

Loading
CNTB
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CNTB vs S&P 500

Performance Gap Between CNTB and GSPC
HIDDEN
Show

Performance By Year
CNTB vs S&P 500

Loading
CNTB
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Connect Biopharma Holdings Ltd vs Peers

S&P 500
CNTB
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Connect Biopharma Holdings Ltd
Glance View

Market Cap
126.6m USD
Industry
Biotechnology

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 108 full-time employees. The company went IPO on 2021-03-19. Its product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD), and asthma. The company is also developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, (S1P1), for the treatment of inflammatory bowel disease (IBD). The firm mainly conducts its businesses in the China market.

CNTB Intrinsic Value
HIDDEN
Show
Back to Top